General Announcement::Glenmark receives tentative ANDA approval for Calcipotriene & Betamethasone Dipropionate Foam

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-May-2022 13:18:27
Status
New
Announcement Sub Title
Glenmark receives tentative ANDA approval for Calcipotriene & Betamethasone Dipropionate Foam
Announcement Reference
SG220509OTHROOUN
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
09/05/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

Attachments

Covering.pdf
Total size =626K